After dropping recently after filing a $150 million shelf offering, Protalix BioTherapeutics (NYSE: PLX) is making a comeback as there ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE